Literature DB >> 26812110

CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.

Sandra Mara Burin1, Sandro Ghisla2, Amanda Tomie Ouchida3, Alexandre Ferro Aissa4, Maria Gabriela Berzoti Coelho5, Tássia Rafaella Costa6, Ana Paula Zambuzi Cardoso Marsola7, Belinda Pinto-Simões8, Lusânia Maria Greggi Antunes9, Carlos Curti10, Suely Vilela Sampaio11, Fabíola Attié de Castro12.   

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Bcr-Abl tyrosine kinase protein, which confers resistance to apoptosis in leukemic cells. Tyrosine kinase inhibitors (TKIs) are effectively used to treat CML; however, CML patients in the advanced (CML-AP) and chronic (CML-CP) phases of the disease are usually resistant to TKI therapy. Thus, it is necessary to seek for novel agents to treat CML, such as the enzyme l-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) snake venom. We examined the antitumor effect of CR-LAAO in Bcr-Abl(+) cell lines and peripheral blood mononuclear cells (PBMC) from healthy subjects and CML patients. CR-LAAO was more cytotoxic towards Bcr-Abl(+) cell lines than towards healthy subjects' PBMC. The H2O2 produced during the enzymatic action of CR-LAAO mediated its cytotoxic effect. The CR-LAAO induced apoptosis in Bcr-Abl(+) cells, as detected by caspases 3, 8, and 9 activation, loss of mitochondrial membrane potential, and DNA damage. CR-LAAO elicited apoptosis in PBMC from CML-CP patients without TKI treatment more strongly than in PBMC from healthy subjects and TKI-treated CML-CP and CML-AP patients. The antitumor effect of CR-LAAO against Bcr-Abl(+) cells makes this toxin a promising candidate to CML therapy.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptosis; CR-LAAO; Calloselasma rhodostoma; Chronic myeloid leukemia; Tyrosine-kinase inhibitors; l-Amino acid oxidase

Mesh:

Substances:

Year:  2016        PMID: 26812110     DOI: 10.1016/j.ijbiomac.2016.01.069

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  5 in total

Review 1.  Antimicrobial properties of L-amino acid oxidase: biochemical features and biomedical applications.

Authors:  Kosuke Kasai; Manabu Nakano; Masami Ohishi; Toshiya Nakamura; Tomisato Miura
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-09       Impact factor: 4.813

2.  CR-LAAO, an L-amino acid oxidase from Calloselasma rhodostoma venom, as a potential tool for developing novel immunotherapeutic strategies against cancer.

Authors:  Tássia R Costa; Danilo L Menaldo; Karina F Zoccal; Sandra M Burin; Alexandre F Aissa; Fabíola A de Castro; Lúcia H Faccioli; Lusânia M Greggi Antunes; Suely V Sampaio
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

3.  BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells.

Authors:  Ana Rita Thomazela Machado; Alexandre Ferro Aissa; Diego Luis Ribeiro; Rui Seabra Ferreira; Suely Vilela Sampaio; Lusânia Maria Greggi Antunes
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2019-03-11

4.  Bothrops moojeni L-amino acid oxidase induces apoptosis and epigenetic modulation on Bcr-Abl+ cells.

Authors:  Sandra Mara Burin; Maira da Costa Cacemiro; Juçara Gastaldi Cominal; Rone Aparecido De Grandis; Ana Rita Thomazela Machado; Flavia Sacilotto Donaires; Adelia Cristina Oliveira Cintra; Luciana Ambrosio; Lusânia Maria Greggi Antunes; Suely Vilela Sampaio; Fabíola Attié de Castro
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-12-14

5.  BthTX-I from Bothrops jararacussu induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation.

Authors:  Patrícia Heloise Alves Bezerra; Isadora Marques Ferreira; Beatriz Tinoco Franceschi; Francine Bianchini; Luciana Ambrósio; Adélia Cristina O Cintra; Suely Vilela Sampaio; Fabíola Attié de Castro; Maria Regina Torqueti
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2019-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.